Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the United States for all approved indications.
Mycophenolate mofetil tablets are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients.
Generic Ablysinol is indicated for the induction of controlled cardiac septal infarction to improve exercise capacity in adult patients with hypertrophic obstructive cardiomyopathy.